



Company Overview

Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as expansion of its flagship FastPack® diagnostic platform. The FastPack® line of FDA-cleared and CE-Marked products has been used successfully in diagnostics since 2002. Our therapeutics pipeline includes cancer drug compounds such as AS1411, AS1411-GNP and RAS-F, as well as STARS, a DNA/RNA-based treatment device. By combining our demonstrated ability to quickly develop and commercialize innovative medical products with the advanced capabilities of leading cancer research centers, such as the University of Louisville, we are committed to providing exciting new therapeutic technologies to physicians and patients.

Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference

Jan 5 2021, 9:00 AM EST

Qualigen Therapeutics Issues CEO Letter to Stockholders with 2021 Outlook

Dec 22 2020, 9:00 AM EST

Qualigen Therapeutics, Inc. Announces Closing of \$12 Million Registered Direct Offering

Dec 18 2020, 3:07 PM EST

Stock Overview

Symbol QLGN
Exchange Nasdaq
Market Cap 90.8m
Last Price \$3.40
52-Week Range \$2.87 - \$21.50

01/15/2021 04:00 PM EST

Investor Relations

LHA Investor Relations
2121 Avenue of the Stars
Suite 2970
Los Angeles, CA 90067
T: 310-691-7100

Management Team

Michael S. Poirier

President, CEO and Chairman

Christopher L. Lotz

Chief Financial Officer

Amy Broidrick

Executive Vice President, Chief Strategy Officer and Director

Shishir K. Sinha

Vice President, Operations, Corporate Secretary

Wajdi Abdul-Ahad, PhD

Vice President, R&D, Chief Scientific Officer

Qualigen Therapeutics, Inc.

2042 Corte del Nogal
Suite B
Carlsbad, CA 92011

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.